Unlikely to be anything in there we've not already been made aware of.
Unless the analysts have medical expertise in dendritic cell therapy and immunology then I imagine it will mostly be marker based info, and would hazard a guess that they'd say it's a high risk stock (duh!). ; )
I think the benefit will be for US investors who have no idea who Prima are. This will serve as an introduction for them to further their own research on.
swot analysis review , page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16911 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 154170 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |